Researchers from the University of South Florida found in a retrospective analysis of clinical trial data that long-term use of monoamine oxidase type B, or MAO-B, inhibitors slows the clinical decline of patients with Parkinson's disease.
Parkinson's decline slowed with extended MAO-B inhibitors - UPI.com